|  **Contact:** |  **Investors:**Progenics                  Pharmaceuticals, Inc.Richard                  W. Krawiec, Ph.D.VP,                  Corporate Affairs(914)                  255-3196rkrawiec@progenics.com  |  **Media:**Aline                  SchimmelWeissComm                  Partners(212)                  301-7218 |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|

**PROGENICS        PRESENTS ADDITIONAL POSITIVE CLINICAL RESULTS FOR HIV-ENTRY INHIBITOR PRO        140 AT        INTERNATIONAL AIDS MEETING**

***–        Significant and prolonged viral load reduction in HIV-infected individuals        after        treatment with single-dose of CCR5 monoclonal antibody PRO        140  –***

*– **Subcutaneous        form of PRO 140 developed for phase 2 clinical        testing**** **–*

**Sydney,        Australia**
*4*
*th*

*        International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment        and        Prevention*

**New        results from phase 1b study**

----

| ·   | For                  individuals receiving the 5 mg/kg dose of PRO 140, there was a                  positive                  trend towards increased numbers of CD4+                  T-cells.  At Day 8, there was an average increase from baseline                  of 129 cells/mm3                  (29%,                  p=0.055) and levels remained elevated for three weeks                  post-treatment.  CD4+                  T-cells are                  major targets of HIV infection, and the number of circulating CD4+                  T-cells                  serves as a key clinical indicator of immune status in HIV-infected                  individuals. CD4+                  T-cell counts                  are an established surrogate marker for monitoring the course of                  HIV                  therapy over time. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| *·  * | Tropism                  testing was performed to assess HIV’s dependence on CCR5 before and after                  PRO 140 treatment. For subjects receiving a single dose of PRO                  140,                  tropism test results showed no change relative to                  placebo. |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | There                  was no significant change in blood levels of RANTES (regulated                  upon                  activation, normal T-cell expressed and secreted) after PRO 140                  treatment.                  RANTES is a chemokine molecule that is produced naturally by the                  body and                  binds to CCR5 on immune system cells. These findings suggest that                  a single                  dose of PRO 140 did not disrupt normal immune function at the doses                  tested                  in this phase 1b study. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

*Interscience Conference on Antimicrobial Agents and Chemotherapy*

----

**Next        steps for PRO 140**

*in        vitro*
*in vitro*

**Previously        announced top-line results of phase 1b study of PRO 140**

**Phase        1b study design**

**About        PRO 140**

----

* in        vitro*

**About        the Company**

*in vivo*

***DISCLOSURE        NOTICE:** The information contained in this document is current as of        July 25, 2007. This press release contains forward-looking statements. Any        statements contained herein that are not statements of historical fact may        be        forward-looking statements. When the Company uses the words "anticipates"'        "plans"' "expects" and similar expressions, it is identifying forward-looking        statements. Such forward-looking statements involve risks and uncertainties        which may cause the Company's actual results, performance or achievements        to be        materially different from those expressed or implied by forward-looking        statements. Such factors include, among others, the uncertainties associated        with product development, the risk that clinical trials will not commence        or        proceed as planned, the risks and uncertainties associated with dependence        upon        the actions of our corporate, academic and other collaborators and of government        regulatory agencies, the risk that our licenses to intellectual property        may be        terminated because of our failure to have satisfied performance milestones,        the        risk that products that appear promising in early clinical trials do not        demonstrate efficacy in larger-scale clinical trials, the risk that we may        not        be able to manufacture commercial quantities of our products, the uncertainty        of        future profitability and other factors set forth more fully in the Company's        Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and        other reports filed with the Securities and Exchange Commission, to which        investors are referred for further information. In particular, the Company        cannot assure you that any of its programs will result in a commercial        product.*

*Progenics        does not have a policy of updating or revising forward-looking statements        and        assumes no obligation to update any forward-looking statements contained        in this        document as a result of new information or future events or developments.        Thus,        it should not be assumed that the Company's silence over time means that        actual        events are bearing out as expressed or implied in such forward-looking        statements.*

----